Wallace Hall

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

ISB Accelerator Corp. is involved in the study of biological systems to help identify strategies for predicting and preventing diseases such as cancer, diabetes and AIDS. The company is located in Seattle, WA.

Part of LeadingSide, Inc., Sovereign Hill Software, Inc. supplies next generation software products. The company is based in Hadley, MA. Sovereign Hill Software was acquired by LeadingSide, Inc. on January 04, 1999 for $1.70 million.

Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses

International Institute of New England, Inc. operates as a non-profit organization serving immigrants, refugees, asylees, and other vulnerable populations. Its services include refugee resettlement, case management, health services navigation, employment, education and literacy and citizenship programming. The company was founded in 1910 and is headquartered in Boston, MA.

Boch Center is a Non-Profit Organisation, which provides arts, entertainment, cultural and educational experience. The company is headquartered in Boston, MA.

Dohmen Co. operates as a retail pharmacy agency that provides outsourced healthcare services. Its services include supply chain, customer and patient support, technology, financial, consulting, and quality and regulatory services. The company was founded by Friedrich W. Dohmen in 1858 and is headquartered in Milwaukee, WI.

Kew, Inc. provides oncology services. It provides multiple services to oncologists to assist in treatment decisions for cancer patients and offers genomic testing for patient tumor samples and genomic information important to diagnostic and treatment decisions that assist physicians and are detailed in cancer-specific Therapeutic Pathways. The company was founded by Richard Bohmer, Viren Mehta, Clayton Matt Christensen, Jeffrey Elton, Mason Freeman, John P. Glaser, H. Robert Horvitz, Bruce Johnson, Kathy Behrens Wilsey and Raju S. Kucherlapat in 2009 and is headquartered in Cambridge, MA.

Part of UBS Group AG, Credit Suisse Global Opportunities Advisors LLC is a company that provides investment advice. The company is based in New York, NY.

Bioleap, Inc. is an engineering services company based in Tampa, FL. Bioleap, Inc. provides engineering services. The private company was founded by Michael S. Wyzga.

Glyscend, Inc. engages in the development of therapeutics for treating metabolic diseases. It focuses on providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. The company was founded by Kevin Colbert in September 2014 and is headquartered in Baltimore, MD.

Carina Biotech Pty Ltd. is an immuno-oncology company based in Mawson Lakes, Australia. The Australian company is developing CAR-T and other adoptive cell therapies to treat solid cancers. Carina Biotech has a deep pipeline of CAR-T programs, including its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer. The private company aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects. Carina Biotech also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell quality, capable of delivering robust “serial-killing” CAR-T cells to patients. The CEO of the company is Deborah A. Rathjen.

Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino.